Cholesterol was rec ognised as the lipid present in the atheromatous plaques in the 1 9 th c entury soon after its disc overy [ 1 ] . The epidemiologic al assoc iation between serum c holesterol or more prec isely serum low-density lipoprotein ( LDL) and c oronary heart disease ( CHD) was well established by the 1 9 6 0 s and the c onfirmation in the 1 9 7 0 s that familial hyperc holesterolaemia was a monogenic disorder due to mutations of LDL rec eptor demonstrated that raised c irc ulating LDL without the need for other CHD risk fac tors c ould c ause ac c elerated atherosc lerosis [ 2 , 3 ] . It was also demonstrated that the c holesterol in atheromatous lesions was derived from LDL c holesterol. Also in the 1 9 7 0 s it was rec ognised that low levels of highdensity lipoprotein ( HDL) were a potent risk fac tor for atherosc lerosis often more important even than LDL in women and older patients [ 4 ] . Raised serum triglyc eride levels have only rec ently bec ome rec ognised as risk fac tors for CHD. Earlier c ontroversy about triglyc erides and CHD risk may have been the c onsequenc e of the greater biologic al variation in the serum triglyc eride c onc entration c ompared to HDL c holesterol with whic h they are relatively strongly c orrelated, whic h meant that triglyc erides were rejec ted in multivariate analysis of CHD risk on mathematic al grounds.
Despite the knowledge that LDL is involved in atherogenesis, its exac t role was until rec ently poorly understood. Although mac rophages were identified as the princ ipal c ell type that gave rise to lipid-laden foam c ells in fatty streaks and mature atherosc lerosis lesions, mac rophages in tissue c ulture displayed little c apac ity to take up LDL. Indeed, mac rophage LDL rec eptor expression is low c ompared to other c ell types suc h as fibroblasts. This c onundrum was solved when it was found that c hemic ally modified LDL ( ac etylated LDL) c ould be rapidly taken up by rec eptors on mac rophages, whic h were not down-regulated, as inc reasing amounts of c holesterol entered their c ytoplasm so that foam-c ell formation oc c urred. Oxidation of LDL ( LDLox) c ould oc c ur in the biosystem and was found to produc e similar rapid uptake of LDL by mac rophages through the ac etyl-LDL rec eptors and through other c lasses of rec eptors.
From_ epidemiologic al and prospec tive studies a qualitative and a quantitative relationship between CHD risk ratio, CHD mortality rate and serum c holesterol c onc entration was dedic ated ( Figure 1 ) . Guidelines, by task forc es of NCEP ( National Cholesterol Educ ation Program) and of Half of all myoc ardial infarc tions oc c ur in persons in whom plasma lipid levels are normal. In an effort to better identify patients at high risk for c ardiovasc ular events, several markers of risk have been proposed for use in sc reening, inc luding homoc ysteine and fibrinogen levels, fibrolytic c apac ity and levels of apolipoprotein A-I, apo B-1 0 0 and Lp ( a) .
With the rec ognition that atherosc lerosis is an inflammatory proc ess, several plasma markers of inflammation have also been evaluated as potential tools for predic tion of the risk of CHD events. Among them are markers of systemic inflammation produc ed in the liver, inc luding high sensitive C-reac tive protein ( hs-CRP) , serum amyloid A, c ytokines suc h as interleukin 6 and soluble interc ellular adhesion molec ule type I ( I CAM-I) .
In Figure 3 the relative risk of future c ardiovasc ular events is desc ribed. Hs-CRP c ombined with the TC/HDL-C ratio is the most pronounc ed risk fac tor for CHD [ 4 ] 
Lipoprotein metabolism
The referenc e method for separation of blood lipoproteins is still the analytic al ultrac entrifugal method, where Gofman and Lindgren developed a method based on density ( g/ml) ( Figure 4 ) .
The elec trophoretic tec hnique ac c ording to Frederic kson c reates the phenotype c lassific ation of the dyslipoproteinaemia. However, it c ontains great genotype variation. The ac tual c lassific ation is based on the biologic al values of the patients: hyperc holesterolaemia, hypertriglyc eridaemia and mixed hyperlipidaemia. The primary hyperlipidaemia based on a genetic defic ienc y is c lassified ac c ording to bioc hemic al mec hanisms.
In Figure 5 , we desc ribe the pathway of lipoprotein metabolism. Synthesis of liver lipids and lipoproteins lead to the formation of the lipoprotein c asc ade and possible to the formation of LDL-oxidised partic les whic h are taken up by SR-A ( sc avenger rec eptor) on the mac rophages or by SR-B rec eptors on the liver. There is also a well-known interac tion between HDL-Lp and low-density lipoproteins where three protein enzymes play an important role for lipid exc hanges: LCAT, lec ithin-c holesterol ac yltransferase; CETP, c holesterol ester transport protein; and PTP, phospholipid transport protein. More attention is paid to the lipoprotein subc lasses, whic h are better known. Chylomic rons ( d< 0 .9 4 g/ml) are from exogenous sourc e and are rapidly metabolised through LpL. If dysfunc tion of the enzyme is present, c hylomic ron remnants are formed, whic h are atherogenic . VLDL ( very low-density lipoprotein) ( 0 .9 > < d> 1 .0 0 6 ) sec reted by the liver has different pathways regulated by LpL and c ell rec eptors. VLDL-1 has two metabolic ways, the major part is taken up by the c ell rec eptor, the minor part is further metabolised via LpL and apo C-II as c ofac tor to VLDL-2 .
VLDL-2 is further degraded to LDL and taken up by apo B/ E or apo B rec eptors to be c atabolized. VLDL remnants due to enzyme dysfunc tions are also atherogenic . LDL partic les are low-density lipoproteins ( 1 .0 1 9 < d < 1 .0 6 0 g/ml) and are c omposed from three major frac tions LDL I, 1 .0 2 0 < d< 1 .0 3 5 ; LDL II, 1 .0 3 5 < d< 1 .0 4 5 g/ml and LDL III, 1 .0 4 5 < d< 1 .0 6 0 g/ml, and are direc t related to the plasma triglyc eride levels. The small LDL partic les have a very low affinity to the c ell rec eptor, are well oxidised and highly atherogenic .
High-density lipoproteins with density range 1 .0 6 3 < d< 1 .0 2 are protein ric h. Three main subgroups are identified as pre-Beta HDL, HDL2 and HDL3 . The interc onversion is determined by exc hange of lipids and lipolytic mec hanisms inc luding the LCAT ac tivity. The size of the partic les is related to the TG plasma levels.
The regulation of HDL subfrac tion distribution is given in Figure 6 . Plasma triglyc eride-ric h ( TG-ric h) lipoproteins, CETP and HDL influenc e the HDL2 /HDL3 distribution in a manner similar to that of LDL subfrac tions. It is postulated that HDL3 c an be c onverted bac k into HDL2 when phospholipid ( PL) and free c holesterol ( FC) , from c ell membranes or from the surfac e of triglyc eride ric h lipoproteins undergoing lipolysis, are integrated into the partic le. LCAT ac tion expands the hydrophobic c ore with CE to generate larger HDL2 partic les. APO A ( I) , shed either from shrinking HDL partic les or from the surfac e of c hylomic rons, or produc ed by de novo synthesis, is believed to interac t with phospholipid and free c holesterol to form a small, prec ursor HDL partic le whic h has pre-Beta migration on elec trophoresis. LCAT ac tion c an c onvert this partic le into mature HDL.
Clinical significance of lipoprotein subclasses
Although high-density lipoprotein ( HDL) and low-density lipoprotein ( LDL) c holesterol levels have long served as the primary indic ators of risk for c oronary heart disease ( CHD) , their diagnostic ac c urac y is limited. In fac t, about half of all individuals who develop heart disease have "normal" HDL and LDL c holesterol levels, and many people with "adverse" c holesterol levels do not develop CHD.
The most c ommon and well-c harac terised lipoprotein metabolic risk is termed the atherogenic lipoprotein phenotype ( ALP) . Present in almost 5 0 % of men with heart disease, the ALP is c harac terised by an over-abundanc e of partic les of the small, dense LDL subc lass in the c irc ulation. People with the same LDL-C level c an have LDL partic les that are predominantly large ( LDL-subc lass pattern A) or small ( LDL-subc lass pattern B) , depending on their metabolic c irc umstanc es. Those with mainly small LDL partic les are likely to have elevated triglyc eride levels and low levels of HDL in the larger subc lasses, whic h are additional c harac teristic s in the ALP.
The tec hniques used most frequently for subc lass frac tionation inc lude various types of ultrac entrifugation, elec trophoresis, c hemic al prec ipitation and c hromatography. They often take several hours to several days to c omplete and usually ac hieve only partial resolution of the subc lasses. It might be possible simultaneously to quantify a large number of lipoprotein subc lasses without employing physic al frac tionation of the plasma. Proton NMR spec trosc opy differenc e exhibited by lipoprotein partic les of different sizes is a new proc ess and a dedic ated intermediate-field ( 3 6 0 MHz) NMR analyser is used.
Figure 5. Pathways of lipoprotein metabolism
There is, for example, abundant evidenc e that LDL partic le size is an important determinant of CDH risk ( 1 ) . Several c ross-sec tional and prospec tive studies have shown that individuals with predominantly small, dense LDL partic les ( subc lass pattern B) are at inc reased risk for CHD even when levels of LDL-C are not elevated. Differing assoc iations of HDL subc lasses with CHD have also been noted. Of the five subc lasses separable by gradient polyac rylamide gel elec trophoresis ( PAGE) , the three largest ( HDL2 b, HDL2 a and HDL3 a) show the expec ted inverse c orrelation with disease inc idenc e and severity, whereas the two smallest subc lasses ( HDL3 b and HDL3 c ) show a positive assoc iation.
Thus, for the same reason that TC is often an unreliable indic ator of CHD risk, HDL-C levels might not ac c urately predic t the degree of CHD protec tion.
The NMR lipoprofiles of two middle-aged men ( patients A and B) illustrate how different the underlying metabolic status and assoc iated risk of CHD c an be for two people who have virtually identic al LDL and HDL c holesterol levels ( Figure 7 ) . In figure we have an example of the type of useful information provided by the NMR Lipo Profile c onc erning individual responsiveness to treatment.
A method more applic able for c linic al work is gradient gel elec trophoresis were the presenc e of two main patterns for LDL subfrac tionation is desc ribed: pattern A, in whic h large LDL predominated; and pattern B, where small LDL was the major spec ies. In Figure 8 regulation of LDL subfrac tionation distribution on PAGE is desc ribed.
LDL in most individuals exists as three disc rete spec ies. In those with low plasma triglyc eride levels ( 0 ,5 -1 ,3 mmol/ l) , larger spec ies ( LDL-I and LDL-II) are most abundant ( giving pattern A on gradient elec trophoresis) , while subjec ts with high normal triglyc eride ( > 1 ,5 mmol/l) have a predominanc e of small, dense LDL-III ( pattern B) . It is postulated that LDL I/II is c onverted into LDL-III by c holesteryl-ester transfer protein ( CETP-mediated exc hange of LDL c holesterylesters ( CE) for triglyc eride from triglyc eride-ric h proteins and subsequent ac tion of hepatic lipase, whic h lipolyses the triglyc eride-enric hed LDL, leading to the formation of a smaller dense spec ies) .
Smaller LDL has a lower affinity for LDL rec eptors than its larger c ounterparts. The metabolic sc heme also predic ts the ac tion of lipid-lowering drugs on the LDL subfrac tions. Agents whic h stimulate LDL rec eptor ac tivity are likely to promote the c learanc e of LDL-I and LDL-II, as has been observed. Plasma triglyc eride-lowering c ompounds on the other hand, shift the patterns from smaller to larger LDLspec ies, as has been seen with fibrates. Insulin resistanc e syndrome is often enc ountered in a series of c linic al situations [ 5 , 6 ] . In everyday prac tic e its most frequent form is that know as syndrome X or plurimetabolic syndrome. It c onsists of several metabolic abnormalities. All of them are rec ognised as independent c ardiovasc ular risk fac tors, espec ially for c oronary artery disease and stroke. The mec hanism relating insulin resistanc e and dyslipidaemia are given in Figure 9 . Over produc tion of gluc ose and triglyc erides lead to formation of small LDL and HDL partic les. We c onsider here the influenc e of low HDL levels and small HDL partic les on c oronary heart disease.
T he metabolic syndrome

GUT
There is no doubt that low levels of HDL-C are assoc iated with an inc reased inc idenc e of c ardiovasc ular events. Multiple mec hanisms may explain how HDL slows progression of atherosc lerosis and retards the development of CHD.
HDL enc ompasses heterogeneous c lasses of lipoproteins whic h have in c ommon a high density ( > 1 .0 6 3 g/ml) and a small size ( Stoke's diameter 2 to 1 7 mm) . The majority of the HDL partic les c ontain apo A-I. Differenc es in the quantitative and qualitative c ontent of lipids, apolipoproteins, enzymes and lipid transfer proteins result in the presenc e of various HDL subc lasses c harac terised by differenc es in shape, density, size, c harge and antigenic ity.
Pathways involved in the generation and conversion of HDL are discussed. Among several causes explaining insulin resistance, it has been speculated that it may be mediated in part by an increase in free fatty acids (FFA), which inhibits postinsulin receptor signalling and contributes to insulin resistance. As resistance to insulin action or insulin deprivation is associated with increased lipolysis, intra-abdominal fat, which is metabolically very active, releases FFA into the portal circulation.
The liver c onverts FFA into triglyc erides and may explain the hypertriglyc eridaemia assoc iated with the plurimetabolic syndrome. The rise in c onc entration of TGenric hed partic les leads to a rec iproc al exc hange of FA: CE to VLDL and c hylomic ron remnants, while TG are transferred to LDL and HDL partic les to form small dense LDL and HDL, whic h are well known for their atherogenic potential.
The low HDL-C syndrome, one fac tor of the metabolic syndrome, often oc c urs with other risk fac tors. Most patients with low levels of HDL also have high triglyc erides, a high proportion of small dense LDL-C partic les and elevated levels of highly atherogenic c hylomic ron remnants. These patients are often obese and frequently have a highly degree of insulin resistanc e, a hyperinsulinaemia, inc reased c onc entrations of plasmogen ac tivator inhibitor ( PAI) and abnormal postprandial lipaemia. As a c onsequenc e therapeutic modific ations of HDL-C levels have attrac ted c onsiderable interest and drugs inc reasing HDL are sought for antiatherogenic therapies. A meta-analysis of four large prospec tive studies has defined the relationship between c hanges in HDL and shifts in CV risk. An inc rease of 0 .2 6 mmol/l reduc ed the inc idenc e of events by 2 % in men and 3 % in women. The protec tive func tions of HDL may explain how the molec ule limit inflammation and mitigate atherogenesis.
It has to be remembered that insulin resistanc e syndrome and type 2 diabetes are two pathologic al c onditions c losely linked to the "Western Way of Life". It would be worth trying to first modify lifestyle by c hanging dietary physic al and rhythm-of-work habits.
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